Pharma: The year that was... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Pharma: The year that was...

May 29, 2007

FY07 was a good year for the Indian pharma companies especially the domestic ones as revenues from exports picked up scale through acquisitions and better opportunity in terms of product launches in the global generics market. The performance of the MNC pharma companies, however, left a lot to be desired. In this article, we shall take a look at the overall performance of the pharma sector for FY07/CY06. We have included the 11 pharma companies under our research coverage for the purpose of the analysis.

FY07: All round improvement
(Rs m) FY06/CY05 FY07/CY06 Change
Sales 195,114 271,922 139.4%
EBDITA 34,318 60,925 177.5%
EBDITA margin (%) 17.6% 22.4%  
Net profit 29,642 44,844 151.3%
Net profit margin (%) 15.2% 16.5%  
* Includes the 11 pharma companies under our research coverage

Both generics and CRAMS did well: FY07/CY06 has been a good year for domestic pharma companies focusing on the generics market. This is because this year represented the largest opportunity in terms of the number and the size of molecules losing patent expiry. Not only that, after a long time, domestic pharma companies were successful in garnering the 180-day exclusivity window for certain molecules allowing them to bolster their overall performance (case in point: Ranbaxy getting the exclusivity for 'Simvastatin 80 mg', Dr.Reddy's being the authorized generic for 'Simvastatin' and 'Finasteride' and also getting the exclusivity for 'Ondansetron' and Sun Pharma for 'Ultracet'). Having said that, the pricing pressure on these molecules, as expected, showed no signs of abating.

FY07 also saw domestic pharma companies making a string of acquisitions in the generics space to expand geographically into Europe and the emerging markets in a bid to reduce dependence on the US market and attain critical scale. These acquisitions also largely contributed to the stellar performance reported by the domestic pharma companies. The year saw a flurry of activity on the CRAMS front as well with the acquisition of Avecia augmenting Nicholas Piramal's performance and the Roche facility in Mexico's lending a fillip to Dr.Reddy's operations.

MNC pharma lagging behind: In comparison to their domestic counterparts, the performance of MNC pharma companies was subdued. MNC companies were slower in launching products from their parent's portfolio with Pfizer being the most aggressive of the lot (3 launches in the domestic market). Also, MNCs have to contend with a higher proportion of the turnover accounting for drugs under the DPCO cover (as compared to their domestic counterparts for whom this proportion is much lesser on account of their emphasis on exports). Going forward, launch of patented products into the country and the pricing of the same will be the key factors that will determine the fortunes of the MNC companies.

Margin picture: Operating margins for the sector (i.e. the 11 companies under our coverage) improved by around 480 basis points. For the domestic companies the margin improvement has come about on account of the 180-day exclusivity period for products enabling them to earn higher margins, efforts to diversify the product mix and increased focus on branded and emerging markets. For MNC companies, margin improvement was largely attributed to the efforts to keep the overheads under control.

Looking ahead...
If one looks at the generics potential year wise, then CY06 did hold the strongest potential in term of patent expiries. Having said that, the global generics market continues to hold potential till CY10. Besides this, consolidation activity is expected to continue in the coming years as well as the pressure to gain scale builds up in wake of the increasing competition. Those companies having a balanced product portfolio and a wider geographical reach will be able to sustain growth in the highly competitive global generics market.

CRAMS will continue to pick up pace as the pressure on global innovator companies to reduce costs continues to mount. In the domestic market, efforts by companies, both domestic and MNC, to keep the product portfolio fresh (largely through in-licensing), will be the key growth drivers. The government's stance on resolving the 'price control' issue will be the key development to watch out for. Thus, from a fundamental view while the domestic market, the global generics market and CRAMS hold strong potential going forward, we advise investors to adopt a stock specific approach while investing in the sector after giving due consideration to valuations.

Equitymaster requests your view! Post a comment on "Pharma: The year that was...". Click here!


More Views on News

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Nov 30, 2021 (Close)